Drug updated on 9/4/2024
Dosage Form | Tablet (oral; 50 mg, 150 mg, 200 mg) |
Drug Class | Kinase inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.
Latest News
Summary
- Piqray (alpelisib) is indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.
- The summary is based on the review of five systematic reviews/meta-analyses. [1-5]
- Alpelisib plus fulvestrant significantly improves Progression-Free Survival (PFS) in HR+/HER2- and PIK3CA-mutated metastatic breast cancer populations compared to fulvestrant alone or anastrozole alone.
- PI3K inhibitors, including alpelisib, show a notable improvement in Overall Response Rate (ORR) for PIK3CA-mutated breast cancer patients, with significant differences observed when compared to placebo.
- No significant difference in Overall Survival (OS) was observed with alpelisib plus fulvestrant compared to other treatments such as abemaciclib, ribociclib, or buparlisib.
- Alpelisib was associated with significant adverse drug events (ADEs), including hyperglycemia (59% all-grade, 28% grade 3/4), diarrhea (56%), nausea (44%), and rash (38%, with 10% grade 3/4). Additionally, 18% of patients discontinued treatment due to ADEs.
- No treatment-related deaths were observed with alpelisib, though there was a high incidence of hyperglycemia and rash among patients.
- The reviewed studies focus primarily on postmenopausal women with HR+, HER2- metastatic breast cancer, with particular attention to PIK3CA-mutated subgroups, underscoring the relevance of PIK3CA mutation testing for personalized treatment approaches in this population.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Piqray (alpelisib) Prescribing Information. | 2024 | Novartis Pharmaceuticals Corporation, East Hanover, NJ |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Biomarkers for systemic therapy in metastatic breast cancer: ASCO guideline update. | 2022 | Journal of Clinical Oncology |
Endocrine treatment and targeted therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO guideline update. | 2021 | Journal of Clinical Oncology |
Treating Breast Cancer. | 2020 | American Cancer Society |
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). | 2020 | Annals of Oncology |